<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with donepezil</title>
<meta name="Author" content="gts (gts_2000@yahoo.com)">
<meta name="Subject" content="RE: Performance enhancement with donepezil">
<meta name="Date" content="2003-01-28">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with donepezil</h1>
<!-- received="Tue Jan 28 20:35:46 2003" -->
<!-- isoreceived="20030129033546" -->
<!-- sent="Tue, 28 Jan 2003 22:36:44 -0500" -->
<!-- isosent="20030129033644" -->
<!-- name="gts" -->
<!-- email="gts_2000@yahoo.com" -->
<!-- subject="RE: Performance enhancement with donepezil" -->
<!-- id="007601c2c747$a847d300$5b2093d0@MyPC" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="BMEDJIBJGLNDOOANGIDLGEEECJAA.rms2g@virginia.edu" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> gts (<a href="mailto:gts_2000@yahoo.com?Subject=RE:%20Performance%20enhancement%20with%20donepezil"><em>gts_2000@yahoo.com</em></a>)<br>
<strong>Date:</strong> Tue Jan 28 2003 - 20:36:44 MST
</p>
<!-- next="start" -->
<ul>
<li><strong>Next message:</strong> <a href="1593.html">Ramez Naam: "RE: Earths difficult?"</a>
<li><strong>Previous message:</strong> <a href="1591.html">spike66: "jr vs k ="</a>
<li><strong>In reply to:</strong> <a href="1536.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<li><strong>Reply:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1592">[ date ]</a>
<a href="index.html#1592">[ thread ]</a>
<a href="subject.html#1592">[ subject ]</a>
<a href="author.html#1592">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Rafal writes:
<br>
<p><em>&gt; ### The data are largely inconclusive, with the studies most
</em><br>
<em>&gt; favorable to selegiline being criticized for methodological failings.
</em><br>
<em>&gt; Coupled with the high cost of Deprenyl, this makes the case for its
</em><br>
<em>&gt; use quite shaky. 
</em><br>
<p>There was, for a short time, fear that use of selegiline in combination
<br>
with levodopa increased mortality rates in Parkinson's patients. However
<br>
subsequent studies proved that fear to be unjustified.
<br>
<p>There is a tremendous amount of favorable research into deprenyl for
<br>
various purposes. It increases lifespan in mice and dogs (and humans,
<br>
hopefully). It's also an excellent antidepressant, especially when taken
<br>
with DL-phenylalanine and B-6 (it increases levels of the natural mood
<br>
enhancer phenylethylamine, and selectively inhibits the MAO-B enzyme
<br>
that breaks down dopamine). It enhances libido. It is neuroprotective;
<br>
it almost certainly prevents or delays the onset of parkinson's disease
<br>
in addition to being a treatment for it. It helps people to quit
<br>
smoking. And it has already been approved as a treatment for cognitive
<br>
dysfunction in senile dogs, under the trade name Anipryl. Yes,
<br>
selegiline makes old dogs smart enough to learn new tricks...
<br>
<p>See <a href="http://www.deprenyl.info">http://www.deprenyl.info</a>
<br>
<p>-gts
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="1593.html">Ramez Naam: "RE: Earths difficult?"</a>
<li><strong>Previous message:</strong> <a href="1591.html">spike66: "jr vs k ="</a>
<li><strong>In reply to:</strong> <a href="1536.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<li><strong>Reply:</strong> <a href="1611.html">Rafal Smigrodzki: "RE: Performance enhancement with donepezil"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#1592">[ date ]</a>
<a href="index.html#1592">[ thread ]</a>
<a href="subject.html#1592">[ subject ]</a>
<a href="author.html#1592">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sun Feb 02 2003 - 21:26:03 MST
</em></small></p>
</body>
</html>
